drugset / Trial / NCT02577783

PDD vs PAD to Treat Initially Diagnosed MM

NCT02577783

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether doxorubicin hydrochloride liposome is superior to doxorubicin when combined with bortizomib and dexamethasone for treating patient with initially diagnosed multiple myeloma.

Timeline

Start
2015-10
Primary completion
2021-10
Completion
2021-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxorubicin Other / unclassified
Background Bortezomib Small molecule
Background Dexamethasone Small molecule

Indications